ADMA Biologics (NASDAQ:ADMA) Shares Down 8.8% – Here’s Why

ADMA Biologics, Inc. (NASDAQ:ADMA) traded down 8.8% during mid-day trading on Monday . The company traded as low as $16.76 and last traded at $16.93. 554,779 shares were traded during trading, a decline of 71% from the average session volume of 1,946,501 shares. The stock had previously closed at $18.56.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Raymond James lifted their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday, November 8th. HC Wainwright lifted their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th.

ADMA Biologics Price Performance

The company has a market cap of $3.86 billion, a price-to-earnings ratio of 58.29 and a beta of 0.76. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The business has a 50-day moving average price of $19.29 and a 200 day moving average price of $17.23.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. During the same period in the previous year, the firm earned $0.01 earnings per share. As a group, research analysts expect that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Insider Activity at ADMA Biologics

In other news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at $4,218,007.95. The trade was a 7.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 3.70% of the stock is owned by insiders.

Institutional Trading of ADMA Biologics

Several large investors have recently modified their holdings of the company. Quest Partners LLC acquired a new position in shares of ADMA Biologics during the second quarter worth approximately $29,000. Hollencrest Capital Management bought a new position in ADMA Biologics during the third quarter worth $30,000. Larson Financial Group LLC acquired a new position in ADMA Biologics during the 3rd quarter valued at $31,000. GAMMA Investing LLC boosted its holdings in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 967 shares during the period. Finally, National Bank of Canada FI bought a new stake in ADMA Biologics in the 3rd quarter valued at $35,000. 75.68% of the stock is owned by institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.